» Articles » PMID: 25367161

Curative Resection of Gallbladder Cancer with Liver Invasion and Hepatic Metastasis After Chemotherapy with Gemcitabine Plus S-1: Report of a Case

Overview
Publisher Biomed Central
Date 2014 Nov 5
PMID 25367161
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

A 62-year-old woman diagnosed with gallbladder cancer exhibiting broad liver invasion and metastasis to Couinaud's hepatic segments 4 and 8 (S4 and S8) consulted her regular doctor. Owing to the presence of liver metastases, she received treatment with gemcitabine plus S-1. After four cycles of chemotherapy, the size of the main lesion dramatically decreased and the two liver metastases disappeared. After six cycles of chemotherapy, the patient was referred to our hospital for surgical treatment. Upon admission, there was no evidence of any distant metastasis, based on a detailed radiological examination. Therefore, we performed cholecystectomy and central bisegmentectomy of the liver after obtaining the patient's informed consent. Pathological examination demonstrated viable cancer cells with granuloma formation and calcification in the gallbladder, as well as regenerative changes without viable cancer cells in S4 and S8 of the liver. Gemcitabine plus S-1 was again administered as postoperative adjuvant chemotherapy. One and a half years after the surgery, there were no signs of recurrence. In patients selected according to their response to chemotherapy, surgical treatment might therefore be effective against gallbladder cancer with metastasis.

Citing Articles

Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway.

He Z, Zhong Y, Regmi P, Lv T, Ma W, Wang J Mol Cancer. 2024; 23(1):65.

PMID: 38532427 PMC: 10967197. DOI: 10.1186/s12943-024-01979-z.


Effects of surgery on survival of elderly patients with gallbladder cancer: A propensity score matching analysis of the SEER database.

Xu X, Wang J, Duan Q Front Oncol. 2023; 13:1083618.

PMID: 36937413 PMC: 10016611. DOI: 10.3389/fonc.2023.1083618.


KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer.

Wei D, Rui B, Qingquan F, Chen C, Ping H, Xiaoling S Int J Biol Sci. 2021; 17(2):514-526.

PMID: 33613109 PMC: 7893577. DOI: 10.7150/ijbs.54074.


Salvage Surgery for Metastatic Gall Bladder Cancer with Vanishing Liver Metastasis Following Palliative 5-Fluorouracil Metronomic Chemotherapy.

Somasekar R, Naganathbabu O, Prabhakaran R, Gnanasekar M, Kannan D J Clin Diagn Res. 2017; 11(5):XD03-XD05.

PMID: 28658893 PMC: 5483795. DOI: 10.7860/JCDR/2017/26460.9938.

References
1.
Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M . Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013; 104(9):1211-6. PMC: 7657216. DOI: 10.1111/cas.12218. View

2.
Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T . A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol. 2013; 71(5):1141-6. PMC: 3636435. DOI: 10.1007/s00280-013-2106-0. View

3.
Lee M, Woo I, Kang J, Hong Y, Lee K . Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol. 2004; 34(9):547-50. DOI: 10.1093/jjco/hyh099. View

4.
Paule B, Herelle M, Rage E, Ducreux M, Adam R, Guettier C . Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007; 72(1-2):105-10. DOI: 10.1159/000111117. View

5.
Hezel A, Zhu A . Systemic therapy for biliary tract cancers. Oncologist. 2008; 13(4):415-23. DOI: 10.1634/theoncologist.2007-0252. View